Madrigal Pharma’s Director Paul Friedman Buys Low, Sells High — Insider Confidence Amid Volatility?
Paul Friedman’s 2026 insider trades: buying Madrigal stock at a steep discount while selling large blocks at high prices – a mixed signal of long‑term conviction and short‑term profit‑taking for investors to consider.
- Madrigal Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
6 minutes to read
